Pipobroman

CHEMBL1585 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
356.0 g/mol
LogP
0.4
Phase
4

Pipobroman is an alkylating antineoplastic agent structurally related to busulfan that exerts its cytotoxic effects by cross-linking DNA strands, thereby inhibiting DNA replication and inducing cell death in rapidly dividing cells. It has been used in the treatment of polycythemia vera and essential thrombocythemia as a myelosuppressive agent.

Moleküler Ağırlık

356,0500 g/mol

LogP

0,40

TPSA

40,60 Ų

Lipinski RO5

Geçer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(CCBr)N1CCN(C(=O)CCBr)CC1

InChI

InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2

Molecular Formula

C10H16Br2N2O2

HBD / HBA

- / 2

Döndürülebilir Bağlar

4

Ağır Atomlar

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Pipobroman is an alkylating antineoplastic agent structurally related to busulfan that exerts its cytotoxic effects by cross-linking DNA strands, thereby inhibiting DNA replication and inducing cell death in rapidly dividing cells. It has been used in the treatment of polycythemia vera and essential thrombocythemia as a myelosuppressive agent.

Yes, Pipobroman is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1585. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4842. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.